Towards the Development
of Life-Saving Vaccines
A clinical stage biotech company focused on making a global impact by developing a state-of-the-art prophylactic vaccine against Group B Streptococcus.
AN INTRODUCTIONWho we are
MinervaX is engaged in the clinical development of a Group B Streptococcal vaccine targeting pregnant women and older adults.
VACCINESTargeting GBS
Our lead candidate AlpN GBS is being tested in the clinic for use in pregnancy or by older people.
INVESTORSMaking our work possible
We are supported by leading blue-chip healthcare funds.
PIPELINEHarnessing science for better protection
Our state-of-the-art vaccine targets important unmet medical needs.
Our investors
OUR MOTIVATIONMinervaX is pursuing the development of a state-of-the-art vaccine
We aim to prevent adverse pregnancy outcomes and life-threatening infections in older people caused by Group B Streptococcus.
To date, we have raised almost EUR 200M via investor syndicates, grants and loans to fast-track and advance the development of our innovative solutions in clinical trials.
INNOVATIONOur pipeline and clinical trials
By using our scientific and development skills we are developing a prophylactic vaccine for use in pregnancy and older people, addressing a strong unmet medical need.
Our approach
We are developing a life-saving vaccine.
Our pipeline
Advancing towards Phase 3 trials.
EXPERIENCE & AGILITYOur team
We have gathered a top team of scientists, vaccine developers, and leaders skilled in corporate development and finance.